Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

China is the fourth major market in which the treatment, sold under the brand name Kisunla, has received approval after the ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

Biogen Inc. (NASDAQ:BIIB), currently trading near its 52-week low at $156.19, finds itself at a critical juncture as it navigates the launch of its Alzheimer's treatment Leqembi while grappling ...

Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States ...

Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030. Challenges ...

Biogen (BIIB) closed near a 52-week low of $150.03. The stock trades at a discount because the biotech firm lacks growth ...

Biogen Inc. (NASDAQ:BIIB), currently trading near its 52-week low at $156.19, finds itself at a critical juncture as it navigates the launch of its Alzheimer's treatment Leqembi while grappling with ...

Biogen faces potential earnings drop of 20-30% by 2030 due to Ocrevus biosimilar competition. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030.

Eisai (ESALY) and Biogen (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk in Mexico has approved humanized ...